Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children

Diane E. T. Bastiaans; Sibyl P. M. Geelen; Eline G. Visser; Michiel van der Flier; Clementien L. Vermont; Angela P. H. Colbers; Monique Roukens; David M. Burger; Annemarie M. C. van Rossum

doi:10.1097/INF.0000000000001964

Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children

Diane E. T. Bastiaans, Sibyl P. M. Geelen, Eline G. Visser, Michiel van der Flier, Clementien L. Vermont, Angela P. H. Colbers, Monique Roukens, David M. Burger, Annemarie M. C. van Rossum

Infectious Diseases patient care

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In this multicenter pharmacokinetic study in HIV-infected children (6–12 years of age), we validated the approved once-daily darunavir/ ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h·mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.

Original language	English
Pages (from-to)	1008-1010
Number of pages	3
Journal	Pediatric Infectious Disease Journal
Volume	37
Issue number	10
DOIs	https://doi.org/10.1097/INF.0000000000001964
Publication status	Published - Oct 2018

Keywords

Children
Darunavir
HIV
Once-daily
Pharmacokinetics

Access to Document

10.1097/INF.0000000000001964

Cite this

Bastiaans, D. E. T., Geelen, S. P. M., Visser, E. G., van der Flier, M., Vermont, C. L., Colbers, A. P. H., Roukens, M., Burger, D. M., & van Rossum, A. M. C. (2018). Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children. Pediatric Infectious Disease Journal, 37(10), 1008-1010. https://doi.org/10.1097/INF.0000000000001964

@article{12153b12c38f40ebbb4c18eaa1d42357,

title = "Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children",

abstract = "In this multicenter pharmacokinetic study in HIV-infected children (6–12 years of age), we validated the approved once-daily darunavir/ ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h·mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.",

keywords = "Children, Darunavir, HIV, Once-daily, Pharmacokinetics",

author = "Bastiaans, {Diane E. T.} and Geelen, {Sibyl P. M.} and Visser, {Eline G.} and {van der Flier}, Michiel and Vermont, {Clementien L.} and Colbers, {Angela P. H.} and Monique Roukens and Burger, {David M.} and {van Rossum}, {Annemarie M. C.}",

year = "2018",

month = oct,

doi = "10.1097/INF.0000000000001964",

language = "English",

volume = "37",

pages = "1008--1010",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams & Wilkins",

number = "10",

}

Bastiaans, DET, Geelen, SPM, Visser, EG, van der Flier, M, Vermont, CL, Colbers, APH, Roukens, M, Burger, DM & van Rossum, AMC 2018, 'Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children', Pediatric Infectious Disease Journal, vol. 37, no. 10, pp. 1008-1010. https://doi.org/10.1097/INF.0000000000001964

Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children. / Bastiaans, Diane E. T.; Geelen, Sibyl P. M.; Visser, Eline G. et al.
In: Pediatric Infectious Disease Journal, Vol. 37, No. 10, 10.2018, p. 1008-1010.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children

AU - Bastiaans, Diane E. T.

AU - Geelen, Sibyl P. M.

AU - Visser, Eline G.

AU - van der Flier, Michiel

AU - Vermont, Clementien L.

AU - Colbers, Angela P. H.

AU - Roukens, Monique

AU - Burger, David M.

AU - van Rossum, Annemarie M. C.

PY - 2018/10

Y1 - 2018/10

N2 - In this multicenter pharmacokinetic study in HIV-infected children (6–12 years of age), we validated the approved once-daily darunavir/ ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h·mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.

AB - In this multicenter pharmacokinetic study in HIV-infected children (6–12 years of age), we validated the approved once-daily darunavir/ ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h·mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.

KW - Children

KW - Darunavir

KW - HIV

KW - Once-daily

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85065494022&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000001964

DO - 10.1097/INF.0000000000001964

M3 - Article

SN - 0891-3668

VL - 37

SP - 1008

EP - 1010

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 10

ER -

Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this